Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome

Table 1 Baseline clinical characteristics of the patients in the two groups

Characteristic	TIPS group (n = 37)	Conservative treatment group (n = 17)	P value
Gender (male/female)	28/9	11/6	0.403
Age (yr)	62.30 ± 10.91	60.18 ± 15.37	0.563
Onset-to-treatment time (d)	28.57 ± 15.26	26.18 ± 12.44	0.535
MELD score	12.13 ± 5.32	12.76 ± 4.96	0.683
Early therapeutic regimen
Reduced glutathione	37 (100)	17 (100)	NA
Ademetionine	37 (100)	17 (100)	NA
Diuretics	37 (100)	17 (100)	NA
Low molecular weight heparin	37 (100)	17 (100)	NA
Glucocorticoids	11 (29.73)	6 (35.29)	0.757
Antibacterial drugs,	23 (62.16)	12 (70.60)	0.549
Clinical symptoms on admission
Ascites (yes/no)	37/0	17/0	NA
Hepatomegaly (yes/no)	26/11	10/7	0.407
Hepatalgia (yes/no)	15/22	7/10	0.965
Peritonitis (yes/no)	7/30	2/15	0.512
Loss of appetite (yes/no)	34/3	15/2	0.667
Gastrointestinal bleeding (yes/no)	1/36	0/17	0.494
Weight gain (yes/no)	12/25	6/11	0.836
Laboratory indicators at 2 wk
Total bilirubin (μmol/L)	53.3 (39.8)	53.6 (45.0)	0.904
Direct bilirubin (μmol/L)	32.4 (32.6)	37.4 (47.0)	0.520
Alanine transaminase (U/L)	45.0 (69.0)	55.0 (86.0)	0.342
Aspartate transaminase (U/L)	65.0 (48.0)	62.0 (89.0)	0.628
Gamma-glutamyl transferase (U/L)	125.0 (90.0)	91.0 (94.0)	0.099
Alkaline phosphatase (U/L)	112.6 (60.0)	95.0 (91.0)	0.087
Albumin (g/L)	31.32 ± 3.38	31.95 ± 4.92	0.588
Prothrombin time (s)	15.81 ± 3.64	16.75 ± 2.28	0.342
White blood cell count (109/L)	6.75 ± 3.05	6.66 ± 2.20	0.913
Neutrophil proportion (%)	64.19 ± 12.16	64.39 ± 10.70	0.955
Red blood cell count (1012/L)	4.91 ± 0.81	4.49 ± 0.63	0.064
Platelet count (109/L)	108.0 (49.0)	90.0 (68.0)	0.165
Blood urea nitrogen (mmol/L)	6.8 (3.4)	5.6 (4.3)	0.252
Creatinine (μmol/L)	67.6 (32.0)	75.0 (35.0)	0.780
Maximum depth of ascites (mm)	95.22 ± 22.58	81.65 ± 26.29	0.057

Data are presented as mean ± standard deviation, median (interquartile range) or n (%). MELD: Model for end-stage liver disease; TIPS: Transjugular intrahepatic portosystemic shunting; NA: Not available.